TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7741785

Group type: EXPERIMENTAL
Intervention: Test formulation (Analgin) containing 1 g of metamizole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation containing 1 g of metamizole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Test formulation (Analgin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12
Study: 1904450

Group type: EXPERIMENTAL
Intervention: 100 mg single dose of melatonin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2.5 mg melatonin in three divided doses (1 mg at 0800 hrs., 0.75 mg at 1000 and 1200 hrs.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6752050

Group type: EXPERIMENTAL
Intervention: Methadone maintenance with 3-day attendance schedule
Number of subjects: 95

Group type: COMPARATOR
Intervention: LAAM maintenance
Number of subjects: 95

Group type: COMPARATOR
Intervention: Methadone maintenance
Number of subjects: 95

Group type: COMPARATOR
Intervention: LAAM maintenance with 3-day attendance schedule
Number of subjects: 95
Study: 30446762

Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA) (FA, Fe 30 mg)
Number of subjects: 18775

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMN) (FA, Fe and 13 micronutrients)
Number of subjects: 18775

Group type: COMPARATOR
Intervention: Folic acid alone (FA) (400 μg)
Number of subjects: 18775

Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA)
Number of subjects: 18775

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMN)
Number of subjects: 18775

Group type: COMPARATOR
Intervention: Folic acid alone (FA)
Number of subjects: 18775
Study: 28872913

Group type: EXPERIMENTAL
Intervention: Edaravone (MCI-186)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26923418

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the left lateral prefrontal cortex during learning phase.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sham) tDCS during learning phase.
Number of subjects: 0
Study: 24590734

Group type: EXPERIMENTAL
Intervention: Communication intervention (PCPs received skills training and standardized patient feedback on counseling behaviors)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Audit-feedback (PCPs received clinical performance feedback)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Communication intervention
Number of subjects: 168
Study: 22516321

Group type: EXPERIMENTAL
Intervention: MS Invigor8 (Internet-based cognitive behavioural therapy self-management programme)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 19681418

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study: 16385545

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg twice daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 75
Study: 14525749

Group type: EXPERIMENTAL
Intervention: Adequate pain control
Number of subjects: 143

Group type: COMPARATOR
Intervention: Inadequate pain control
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Any analgesics accepted
Number of subjects: 143

Group type: COMPARATOR
Intervention: No analgesic need
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Parenteral analgesics accepted
Number of subjects: 143
Study: 11020621

Group type: EXPERIMENTAL
Intervention: Array(R) foldable multifocal IOL (model SA‐40N, Allergan)
Number of subjects: 124

Group type: COMPARATOR
Intervention: AMO(R) PhacoFlex II(R) silicone monofocal IOL (model SI‐40NB)
Number of subjects: 124
Study: 8866535

Group type: EXPERIMENTAL
Intervention: Neurobehavioral Evaluation System (NES) tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional neuropsychological tests
Number of subjects: 0
Study: 1738969

Group type: EXPERIMENTAL
Intervention: Uppsala screws
Number of subjects: 179

Group type: COMPARATOR
Intervention: Hansson pins
Number of subjects: 179
Study: 6337982

Group type: EXPERIMENTAL
Intervention: Inhaled atropine (0.5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous atropine (0.5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Inhaled and intravenous placebos
Number of subjects: 6
Study: 31507054

Group type: EXPERIMENTAL
Intervention: Statin therapy (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent statin dosing, new LDL-lowering drugs, LDL apheresis, and supplements (specific details not mentioned)
Number of subjects: 0
Study: 28118323

Group type: EXPERIMENTAL
Intervention: Chemotherapy (weekly paclitaxel 80 mg/m² or four weekly pegylated liposomal doxorubicin 40 mg/m²)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Tamoxifen (40 mg daily)
Number of subjects: 238
Study: 25290597

Group type: EXPERIMENTAL
Intervention: NEAT Girls intervention for obesity prevention
Number of subjects: 294
Study: 23902483

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 119
Study: 21763893

Group type: EXPERIMENTAL
Intervention: Ledermix
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ultracal XS
Number of subjects: 22
Study: 19447919

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16527576

Group type: EXPERIMENTAL
Intervention: BCG (six weekly instillations of 80 mg BCG [Tokyo 172 strain])
Number of subjects: 80

Group type: COMPARATOR
Intervention: Doxorubicin (17 instillations of 20 mg doxorubicin)
Number of subjects: 80
Study: 15471823

Group type: EXPERIMENTAL
Intervention: NOGA mapping of endocardial unipolar voltage
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 201Tl SPECT
Number of subjects: 21
Study: 11133606

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg IV
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 9753020

Group type: EXPERIMENTAL
Intervention: Gentamicin once a day with ticarcillin-clavulanate (TC)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Gentamicin three times a day with ticarcillin-clavulanate (TC)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Ticarcillin-clavulanate (TC) alone
Number of subjects: 249
Study: 7790757

Group type: EXPERIMENTAL
Intervention: trapidil 200 mg tablets bid
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 2899451

Group type: EXPERIMENTAL
Intervention: Esmolol infusion at a dose rate of 80 +/- 59 micrograms/kg/min
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 48
Study: 28885667

Group type: EXPERIMENTAL
Intervention: Trifocal intraocular lens (IOL) implantation (FineVision and AT LISA tri 839MP)
Number of subjects: 50
Study: 26588810

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) therapy with subcutaneous insulin via CL pump (n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Multiple daily injections with blinded continuous glucose monitor (CGM) (n = 7)
Number of subjects: 14
Study: 25623207

Group type: EXPERIMENTAL
Intervention: High achievement orientation
Number of subjects: 155

Group type: COMPARATOR
Intervention: Low achievement orientation
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: High social orientation
Number of subjects: 155

Group type: COMPARATOR
Intervention: Low social orientation
Number of subjects: 155
Study: 23363373

Group type: EXPERIMENTAL
Intervention: Galactagogue herbal tea (Humana still-tee®, Herford, Deutschland) 3 cups/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Water as placebo (3 cups/d)
Number of subjects: 80
Study: 21094848

Group type: EXPERIMENTAL
Intervention: Equoral
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both Equoral and Neoral
Number of subjects: 30
Study: 19006503

Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17213007

Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg (older group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tolerability assessment
Number of subjects: 31
Study: 12617376

Group type: EXPERIMENTAL
Intervention: Whole‐plant extracts of delta‐9‐tetrahydrocannabinol (THC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Whole‐plant extracts of cannabidiol (CBD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cannabis medicinal extracts (CME)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: THC-containing CME
Number of subjects: 24
Study: 10952113

Group type: EXPERIMENTAL
Intervention: Six-level preview method
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional preview method
Number of subjects: 240
Study: 9080890

Group type: EXPERIMENTAL
Intervention: Educational brochure illustrating typical changes of melanoma
Number of subjects: 93

Group type: COMPARATOR
Intervention: No educational brochure (control group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 93
Study: 8442620

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg orally once daily or 200 mg intravenously every 12 hours)
Number of subjects: 257
Study: 3620399

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: No oxytocin infusion (control)
Number of subjects: 60
Study: 31909811

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) - 20 g daily during pregnancy and 6 months postpartum; infants received LNS from 6 to 18 months.
Number of subjects: 869

Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN) - 1 capsule daily during pregnancy and 6 months postpartum; combined with IFA group for analysis.
Number of subjects: 869

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) - 1 capsule daily during pregnancy, then placebo postpartum; combined with MMN group for analysis.
Number of subjects: 869
Study: 30430209

Group type: EXPERIMENTAL
Intervention: Low-normal PaCO2 (4.5-4.7 kPa)
Number of subjects: 123

Group type: COMPARATOR
Intervention: High-normal PaCO2 (5.8-6.0 kPa)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Normoxia (PaO2 10-15 kPa)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Moderate hyperoxia (PaO2 20-25 kPa)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: High-normal PaCO2
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Moderate hyperoxia
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 123
Study: 26940848

Group type: EXPERIMENTAL
Intervention: User comments addressing tentativeness
Number of subjects: 70

Group type: COMPARATOR
Intervention: User comments not addressing tentativeness
Number of subjects: 70

Group type: COMPARATOR
Intervention: No user comments
Number of subjects: 70
Study: 25223267

Group type: EXPERIMENTAL
Intervention: OPV0+BCG
Number of subjects: 430

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 430
Study: 21831580

Group type: EXPERIMENTAL
Intervention: Subvastus (SV) approach
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medial Parapatellar (MP) approach
Number of subjects: 90
Study: 19110245

Group type: EXPERIMENTAL
Intervention: Integrated yoga practice and guided yogic relaxation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard prenatal exercises
Number of subjects: 122
Study: 17642233

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: golimumab
Number of subjects: 0
Study: 15987403

Group type: EXPERIMENTAL
Intervention: Oatmeal formula fermented with Lactobacillus plantarum 299v (Lp 299v)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17
Study: 12363007

Group type: EXPERIMENTAL
Intervention: Reduced antimicrobial usage (from 1.5 to 1.1 courses/year)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Overall antimicrobial use among children <7 years old (from 13.6 to 11.1 defined daily dosages/1000 children per day)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Community-wide interventions to reduce antimicrobial usage
Number of subjects: 743
Study: 9609785

Group type: EXPERIMENTAL
Intervention: High-CHO diet (HiCHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-CHO diet (LoCHO)
Number of subjects: 10
Study: 7815103

Group type: EXPERIMENTAL
Intervention: Timed nine hole peg test
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10 meter walk test
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Williams delayed recall test
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Boston Aphasia Severity Rating Scale
Number of subjects: 50

Group type: COMPARATOR
Intervention: Barthel Disability Index (BDI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Number of abnormal fast tests
Number of subjects: 50
Study: 1704561

Group type: EXPERIMENTAL
Intervention: Steroid-tipped leads
Number of subjects: 18

Group type: COMPARATOR
Intervention: Porous platinum leads
Number of subjects: 18
Study: 70320

Group type: EXPERIMENTAL
Intervention: Tape-slide program
Number of subjects: 180

Group type: COMPARATOR
Intervention: Tape-slide program alone
Number of subjects: 180
Study: 31937123

Group type: EXPERIMENTAL
Intervention: Patient-Directed Activity Program (PDAP)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Patient-Directed Activity Program (PDAP) at three months post discharge
Number of subjects: 73
Study: 31164185

Group type: EXPERIMENTAL
Intervention: Pharmacists
Number of subjects: 101

Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 101
Study: 28488553

Group type: EXPERIMENTAL
Intervention: Intensive vascular care in GP practices
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study: 26506205

Group type: EXPERIMENTAL
Intervention: Hydration bladder (BG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional canteen (CG)
Number of subjects: 0
Study: 24383602

Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Levobupivacaine plus 1 μg·kg(‐1) dexmedetomidine
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Levobupivacaine plus 2 μg·kg(‐1) dexmedetomidine
Number of subjects: 89
Study: 21672910

Group type: EXPERIMENTAL
Intervention: CHICA system intervention (tailored prompt for TB and iron-deficiency anemia)
Number of subjects: 2239

Group type: COMPARATOR
Intervention: Control group (generic prompt, no screening)
Number of subjects: 2239
Study: 19309747

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil once daily for 4 weeks (Phase 1)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Continued modafinil for an additional 4 weeks (Phase 2)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (Phase 2)
Number of subjects: 82
Study: 16750463

Group type: EXPERIMENTAL
Intervention: Sumatriptan 4 mg SC
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study: 15729231

Group type: EXPERIMENTAL
Intervention: Multipolar electrocoagulation (MPEC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 52
Study: 12860797

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Number of subjects: 31
Study: 10206720

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh, 0.55 M)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal polypeptide (VIP, 1.5x 10(‐5) M)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of ACh and VIP
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cetirizine (H1-antagonist) pretreatment before ACh injection
Number of subjects: 14
Study: 7486088

Group type: EXPERIMENTAL
Intervention: Epidural 0.1% ropivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural 0.2% ropivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural 0.3% ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural saline (control)
Number of subjects: 40
Study: 2360502

Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg once daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 to 800 mg once daily)
Number of subjects: 39
Study: 7026343

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 532

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 532
Study: 29672306

Group type: EXPERIMENTAL
Intervention: Bladder training (Arm A)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) (Arm B)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: PFMT with biofeedback (Arm C)
Number of subjects: 147
Study: 28718910

Group type: EXPERIMENTAL
Intervention: Housing subsidies plus housing case management
Number of subjects: 75

Group type: COMPARATOR
Intervention: Housing case management alone
Number of subjects: 75
Study: 26044228

Group type: EXPERIMENTAL
Intervention: Ultrasound and water capsule-guided local injection of botulinum toxin type A (group B)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Oral drug treatment (group A)
Number of subjects: 157
Study: 23108953

Group type: EXPERIMENTAL
Intervention: AMG 386 (10 mg/kg QW) plus cisplatin/capecitabine (CX)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: AMG 386 (3 mg/kg QW) plus cisplatin/capecitabine (CX)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo plus cisplatin/capecitabine (CX)
Number of subjects: 171
Study: 22030577

Group type: EXPERIMENTAL
Intervention: Reiki treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (Hand-off sham intervention)
Number of subjects: 18
Study: 18672290

Group type: EXPERIMENTAL
Intervention: Nilvadipine (2 mg twice daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 17039647

Group type: EXPERIMENTAL
Intervention: Orapred
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pediapred
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: dexamethasone suspension
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: prednisone suspension
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: cherry‐flavored prednisolone suspensions
Number of subjects: 31
Study: 12694213

Group type: EXPERIMENTAL
Intervention: Carriers of TNFA-308*1/2 (*G/A) genotype
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Carriers of TNFA-308*2/2 (*A/A) genotype
Number of subjects: 86

Group type: COMPARATOR
Intervention: TNFA-308 genotypes distribution
Number of subjects: 86
Study: 11885186

Group type: EXPERIMENTAL
Intervention: Post-loading method
Number of subjects: 829

Group type: COMPARATOR
Intervention: All failures counted
Number of subjects: 829
Study: 9005589

Group type: EXPERIMENTAL
Intervention: Mitomycin-C 30 mg for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mitomycin-C 40 mg for 6 months
Number of subjects: 60
Study: 1471536

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 151

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 151
Study: 6376827

Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethoglucid (Epodyl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 0
Study: 29787483

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 27297772

Group type: EXPERIMENTAL
Intervention: TMS at 40% of maximal stimulator output
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TMS at 70% of maximal stimulator output
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Single-pulse PNS
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Paired (100-Hz)-pulse PNS
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Single-pulse EMS
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Expectation of TMS at 70% of maximal stimulator output
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Expectation of paired-pulse PNS
Number of subjects: 19

Group type: COMPARATOR
Intervention: No stimulation (control condition)
Number of subjects: 19
Study: 25540035

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral couple therapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Topical lidocaine
Number of subjects: 170
Study: 23316598

Group type: EXPERIMENTAL
Intervention: Experimental group receiving preventive measures designed for each risk category applied periodically.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving standardized preventive measures at regular intervals.
Number of subjects: 0
Study: 19895780

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/d
Number of subjects: 70
Study: 18794543

Group type: EXPERIMENTAL
Intervention: Docetaxel and Estramustine (D/E); 280 mg orally three times a day on days 1 to 5 and 8 to 12, every 3 weeks, plus prednisone (10 mg/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Docetaxel alone (D); 35 mg/m(2) on days 2 and 9, every 3 weeks, plus prednisone (10 mg/d)
Number of subjects: 150
Study: 15887946

Group type: EXPERIMENTAL
Intervention: Case conferences conducted via teleconference
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Case conferences
Number of subjects: 56
Study: 12766861

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg daily)
Number of subjects: 1987

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1987
Study: 12372154

Group type: EXPERIMENTAL
Intervention: Iron pots
Number of subjects: 113

Group type: COMPARATOR
Intervention: Aluminium pots
Number of subjects: 113